Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature

CAN BOSTAN Ö., KARAKAYA G., KALYONCU A. F., DAMADOĞLU E.

Journal of Asthma, vol.61, no.3, pp.260-264, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 61 Issue: 3
  • Publication Date: 2024
  • Doi Number: 10.1080/02770903.2023.2260884
  • Journal Name: Journal of Asthma
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, Psycinfo, Veterinary Science Database
  • Page Numbers: pp.260-264
  • Keywords: chronic spontaneous urticarial, dual biologics, mepolizumab, omalizumab, Severe asthma
  • Hacettepe University Affiliated: Yes

Abstract

Introduction: The data on the use of dual biologics are scant, but a topic of current interest. Case Study: In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented. Results: Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use. Conclusion: This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature.